Literature DB >> 28705498

[Hepatonephritis during the treatment of malaria by the therapeutic combinations from a pharmacovigilance database].

Mamadou Kamagaté1, Check Oumar Diallo2, David Meless3, Thérèse Daubrey-Potey4, Augustine Kakou4, Éric Balayssac4, Kanga Sita N'zue2, Jean Claude Yavo4, Henri Die-Kakou4.   

Abstract

INTRODUCTION: Prior studies have shown an association between the onset of hepatonephritis and the use of arteminisin-based combination therapy (ACT) during the treatment of uncomplicated malaria. The objective of this study was to identify the risk factors of hepatonephritis occurrence because of the uncertainty regarding the appearance and the aggravation of this syndrome.
METHODS: A case-non case study was carried out on 428 notifications of pharmacovigilance extracted from the database of the clinical pharmacology department of the teaching hospital of Cocody from 2008 to 2012. Twenty-two cases of hepatonephritis were identified. Univariate analysis and multivariate logistic regression were performed to identify the risk factors and an adjusted odds ratio (AOR) was calculated for each factor. The cut-off for significant association was set at 0.05.
RESULTS: The average age of cases was comparable with that of non-cases (34.04±3.68 years versus 33.94±3.92 years) with a median duration of therapy of 5 days and 6 days respectively. Male (AOR: 6.71; P<0.0001), toxic antecedents, traditherapy (AOR: 6.25; P<0.0001), consumption of CTA (AOR: 1.25; P<0.0001), betalactam (AOR: 0.46; P<0.0001), fluoroquinolone and self-medication (AOR: 2.89; P<0.0001) would be the majors risk factors associated with hepatonephritis onset. The risk increased with the number of antimalarial drugs taken. The evolution towards the offset was less frequent (AOR: 0.078; P<0.02).
CONCLUSION: The risk factors of hepatonephritis were the consumption of malarial drugs and connected molecules, self-medication and misuse. The outcome was generally unfavourable. Both the general population and health professionals should be trained on the good use of the antimalarial drugs.
Copyright © 2017 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antimalarial drugs; Antipaludiques; Facteurs de risque; Hepatonephritis; Hepatorenal syndrome; Hépatonéphrite; Pharmacovigilance; Risk factors; Syndrome hépatorénal

Mesh:

Substances:

Year:  2017        PMID: 28705498     DOI: 10.1016/j.therap.2017.03.001

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  1 in total

1.  Artemisinin-Based Combination Therapy Synergized with Medicinal Plants to Induce Musculotoxic Effects.

Authors:  Thérèse Daubrey-Potey; Valéry Adjogoua; Mamadou Kamagaté; Serges Aoussi; Mireille Dosso
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-08       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.